Journal of Geriatric Cardiology
|
2026, 23(9): 647-654
• LETTER TO THE EDITOR •
Immune checkpoint inhibitor-induced myocarditis with third-degree atrioventricular block: two case reports and literature review
Full
Natasha Kalombo
1, Liang Xu
2, Ke Li
1, Yunjie Yin
2, Han Tang
2, Wei Zhong
1, ✉, Ye Zhou
1, ✉
Affiliations
- 1.Department of Cardiology, Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, China
- 2.Department of Cardiology, Affiliated Yi Xing Hospital of Jiangsu University, Wuxi, Jiangsu, China
About Author:
*
The authors contributed equally to this manuscript
Published: 2026-09-28
doi: 10.26599/1671-5411.2026.09.004
Outline
Natasha Kalombo, Liang Xu, Ke Li, Yunjie Yin, Han Tang, Wei Zhong, Ye Zhou.
Immune checkpoint inhibitor-induced myocarditis with third-degree atrioventricular block: two case reports and literature review.
老年心脏病杂志（英文）,
2026
, 23
(9)
: 647
-654
.
DOI: 10.26599/1671-5411.2026.09.004
Natasha Kalombo, Liang Xu, Ke Li, Yunjie Yin, Han Tang, Wei Zhong, Ye Zhou.
Immune checkpoint inhibitor-induced myocarditis with third-degree atrioventricular block: two case reports and literature review[J].
Journal of Geriatric Cardiology,
2026
, 23
(9)
: 647
-654
.
DOI: 10.26599/1671-5411.2026.09.004
- This study was supported by the Natural Science Foundation of China (82000261), Natural Science Research in Universities of Jiangsu Province (BE2021694), and the Social Development Foundation of Zhenjiang (SH2024033, SH2024086).
[1]
Koelmeyer H, Buckley K, Feradov D, Kotch N. Complete heart block in a patient undergoing combination immune checkpoint inhibitor therapy.
Cureus 2024; 16: e66776.
[2]
Su L, Liu C, Wu W,
et al. Successful therapy for myocarditis concomitant with complete heart block after pembrolizumab treatment for head and neck squamous cell carcinoma: a case report with literature review.
Front Cardiovasc Med 2022; 9: 898756.
[3]
Johnson DB, Balko JM, Compton ML,
et al. Fulminant myocarditis with combination immune checkpoint blockade.
N Engl J Med 2016; 375: 1749-1755.
[4]
Varricchi G, Galdiero MR, Tocchetti CG. Cardiac toxicity of immune checkpoint inhibitors: cardio-oncology meets immunology.
Circulation 2017; 136: 1989-1992.
[5]
Behling J, Kaes J, Munzel T,
et al. New-onset third-degree atrioventricular block because of autoimmune-induced myositis under treatment with anti-programmed cell death-1 (nivolumab) for metastatic melanoma.
Melanoma Res 2017; 27: 155-158.
[6]
Reddy N, Moudgil R, Lopez-Mattei JC,
et al. Progressive and reversible conduction disease with checkpoint inhibitors.
Can J Cardiol 2017; 33: 1335. e13-e15.
[7]
Frigeri M, Meyer P, Banfi C,
et al. Immune checkpoint inhibitor-associated myocarditis: a new challenge for cardiologists.
Can J Cardiol 2018; 34: 92. e1-e3.
[8]
Fukasawa Y, Sasaki K, Natsume M,
et al. Nivolumab-induced myocarditis concomitant with myasthenia gravis.
Case Rep Oncol 2017; 10: 809-812.
[9]
Tay RY, Blackley E, McLean C, Moore M, Bergin P, Gill S. Successful use of equine anti-thymocyte globulin (ATGAM) for fulminant myocarditis secondary to nivolumab therapy.
Br J Cancer 2017; 117: 921-924.
[10]
Katsume Y, Isawa T, Toi Y,
et al. Complete atrioventricular block associated with pembrolizumab-induced acute myocarditis: the need for close cardiac monitoring.
Intern Med 2018; 57: 3157-3162.
[11]
Szuchan C, Elson L, Alley E,
et al. Checkpoint inhibitor-induced myocarditis and myasthenia gravis in a recurrent/metastatic thymic carcinoma patient: a case report.
Eur Heart J Case Rep 2020; 4: 1-8.
[12]
Luo YB, Tang W, Zeng Q,
et al. The neuromusclar triad of immune checkpoint inhibitors: a case report of myositis, myocarditis, and myasthenia gravis overlap following toripalimab treatment.
Front Cardiovasc Med 2021; 8: 714460.
[13]
Jespersen MS, Stenor C, Moller AK. A case report of immune checkpoint inhibitor-related steroid-refractory myocarditis and myasthenia gravis-like myositis treated with abatacept and mycophenolate mofetil.
Eur Heart J Case Rep 2021; 5: ytab342.
[14]
Doms J, Prior JO, Peters S, Obeid M. Tocilizumab for refractory severe immune checkpoint inhibitor-associated myocarditis.
Ann Oncol 2020; 31: 1273-1275.
[15]
Xing Q, Zhang ZW, Lin QH,
et al. Myositis-myasthenia gravis overlap syndrome complicated with myasthenia crisis and myocarditis associated with anti-programmed cell death-1 (sintilimab) therapy for lung adenocarcinoma.
Ann Transl Med 2020; 8: 250.
[16]
Yanase T, Moritoki Y, Kondo H,
et al. Myocarditis and myasthenia gravis by combined nivolumab and ipilimumab immunotherapy for renal cell carcinoma: a case report of successful management.
Urol Case Rep 2021; 34: 101508.
[17]
Kondo H, Kirigaya J, Matsuzawa Y, Hibi K. Two cases of immune checkpoint inhibitor-induced myocarditis with complete atrioventricular block.
Cureus 2023; 15: e36446.
[18]
Saad R, Ghaddar A, Zeenny RM. Pembrolizumab-induced myocarditis with complete atrioventricular block and concomitant myositis in a metastatic bladder cancer patient: a case report and review of the literature.
J Med Case Rep 2024; 18: 107.
[19]
Lorente-Ros A, Rajjoub-Al-Mahdi EA, Monteagudo Ruiz JM,
et al. Checkpoint immunotherapy-induced myocarditis and encephalitis complicated with complete AV block.
JACC Case Rep 2022; 4: 1032-1036.
[20]
Berg DD, Vaduganathan M, Nohria A,
et al. Immune-related fulminant myocarditis in a patient receiving ipilimumab therapy for relapsed chronic myelomonocytic leukaemia.
Eur J Heart Fail 2017; 19: 682-685.
[21]
Nasr F, El Rassy E, Maalouf G,
et al. Severe ophthalmoplegia and myocarditis following the administration of pembrolizumab.
Eur J Cancer 2018; 91: 171-173.
[22]
Jain V, Mohebtash M, Rodrigo M,
et al. Autoimmune myocarditis caused by immune checkpoint inhibitors treated with anti-thymocyte globulin.
J Immunother 2018; 41: 332-335.
[23]
Martinez-Calle N, Rodriguez-Otero P, Villar S,
et al. Anti-PD1 associated fulminant myocarditis after a single pembrolizumab dose: the role of occult pre-existing autoimmunity.
Haematologica 2018; 103: e318-e321.
[24]
Saibil SD, Bonilla L, Majeed H,
et al. Fatal myocarditis and rhabdomyositis in a patient with stage IV melanoma treated with combined ipilimumab and nivolumab.
Curr Oncol 2019; 26: e418-e421.
[25]
Charles J, Giovannini D, Terzi N,
et al. Multi-organ failure induced by nivolumab in the context of allo-stem cell transplantation.
Exp Hematol Oncol 2019; 8: 8.
[26]
Hardy T, Yin M, Chavez JA,
et al. Acute fatal myocarditis after a single dose of anti-PD-1 immunotherapy, autopsy findings: a case report.
Cardiovasc Pathol 2020; 46: 107202.
[27]
Giancaterino S, Abushamat F, Duran J,
et al. Complete heart block and subsequent sudden cardiac death from immune checkpoint inhibitor-associated myocarditis.
HeartRhythm Case Rep 2020; 6: 761-764.
[28]
Portoles Hernandez A, Blanco Clemente M, Escribano Garcia D,
et al. Checkpoint inhibitor-induced fulminant myocarditis, complete atrioventricular block and myasthenia gravis-a case report.
Cardiovasc Diagn Ther 2021; 11: 1013-1019.
[29]
Komatsu M, Hirai M, Kobayashi K,
et al. A rare case of nivolumab-related myasthenia gravis and myocarditis in a patient with metastatic gastric cancer.
BMC Gastroenterol 2021; 21: 333.
[30]
Barham W, Guo R, Park SS,
et al. Case report: simultaneous hyper-progression and fulminant myocarditis in a patient with advanced melanoma following treatment with immune checkpoint inhibitor therapy.
Front Immunol 2020; 11: 561083.
[31]
Wang F, Sun X, Qin S,
et al. A retrospective study of immune checkpoint inhibitor-associated myocarditis in a single center in China.
Chin Clin Oncol 2020; 9: 16.
[32]
González-Ferrero T, Vargas-Osorio K, González-Juanatey JR. Fulminant myocarditis with myositis after treatment with immune checkpoint inhibitors.
Med Clin (Barc) 2022; 158: 140-141.
[33]
Vartanov A, Kalotra A, Varughese J, Gautam S, Kandel S, Hosmer W. Immunotherapy-associated complete heart block in a patient with NSCLC: a case report and literature review.
Respir Med Case Rep 2021; 33: 101390.
[34]
Naganuma K, Horita Y, Matsuo K,
et al. An autopsy case of late-onset fulminant myocarditis induced by nivolumab in gastric cancer.
Intern Med 2022; 61: 2867-2871.
Year 2026 volume 23 Issue 9
PDF
9
1
Cite this Article
BibTeX
Article Info
doi: 10.26599/1671-5411.2026.09.004
- Online Date：2026-10-30
- Published：2026-09-28
关闭全屏
No. 86 Xueyuan South Road, Haidian District, Beijing
010-62662699(Operation and Technical Support)
qkjq@cast.org.cn
